Tyrosine kinase inhibitors in acute and chronic leukemias

Author： Ohanian Maro Cortes Jorge Kantarjian Hagop Jabbour Elias

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.7, 2012-05, pp. : 927-938

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibody Therapy of Acute and Chronic Leukemias

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 357-367

Bentham Science Publishers

Access to resources Recommend Favorite

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

By Radich Jerald P. Oehler Vivian

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 497-504

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 201-213

Bentham Science Publishers

Access to resources Recommend Favorite

Selective tyrosine kinase inhibitors

By Wilkinson S.E. Harris W.

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 287-297

Informa Healthcare

Access to resources Recommend Favorite